Active substance
Candesartan
- SFDA 19
- US FDA 8
- Health Canada 52
- US price lines 6
- NHS prices 5
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ATACAND 16 MG TAB | 16 mg | Tablet · Oral use | 28 Blister | SAR 67.35 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| ATACAND 32MG TABLETS | 32 mg | Tablet · Oral use | 28 Blister | SAR 94.85 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| ATACAND 8 MG TAB | 8 mg | Tablet · Oral use | 28 Blister | SAR 55.10 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| BLOPRESS 16 MG TABLETS | 16 mg | Tablet · Oral use | 28 Blister | SAR 54.65 | Generic · Prescription | APM | Valid |
| BLOPRESS 8MG TAB. | 8 mg | Tablet · Oral use | 28 Blister | SAR 47.70 | Generic · Prescription | APM | Valid |
| CANDAN | 8 mg | Tablet · Oral use | 28 Blister | SAR 23.45 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| CANDAN 16 mg tablet | 16 mg | Tablet · Oral use | 28 Blister | SAR 45.85 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| CANDEZA 16 mg Tablet | 16 mg | Tablet · Oral use | 28 Blister | SAR 34.45 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CANDEZA 8 mg Tablet | 8 mg | Tablet · Oral use | 28 Blister | SAR 23.45 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| DICERAN 16 mg film-coated tablet | 16 mg | Tablet · Oral use | 28 Blister | SAR 28.30 | Generic · Prescription | SANDOZ | Valid |
| DICERAN 8 mg film-coated tablet | 8 mg | Tablet · Oral use | 28 Blister | SAR 23.45 | Generic · Prescription | SANDOZ | Valid |
| GARDIA 16MG TABLETS | 16 mg | Tablet · Oral use | 30 Blister | SAR 34.45 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| ATACAND 4 MG TAB | 4 mg | Tablet · Oral use | 28 Blister | SAR 50.20 | NCE · Prescription | AstraZeneca AG | Withdrawn by MAH · Not Marketed |
| CANDEPRESS 16 mg tablet | 16 mg | Tablet · Oral use | 30 Blister | SAR 54.60 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CANDEPRESS 32 mg tablet | 32 mg | Tablet · Oral use | 30 Blister | SAR 77.10 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CANDEPRESS 4 mg tablet | 4 mg | Tablet · Oral use | 30 Blister | SAR 40.75 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CANDEPRESS 8 mg tablet | 8 mg | Tablet · Oral use | 30 Blister | SAR 44.75 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CANDEZA 32 mg Tablet | 32 mg | Tablet · Oral use | 28 Blister | SAR 46.35 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| CANDEZA 4 mg Tablet | 4 mg | Tablet · Oral use | 28 Blister | SAR 23.45 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HYPERTENSION; SICKLE CELL DISEASE - ALBUMINURIA MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ATACAND | 4MG; 8MG; 16MG; 32MG | tablet · oral | ANI PHARMS | Prescription | 4 Jun 1998 |
| CANDESARTAN CILEXETIL | 4MG; 8MG; 16MG; 32MG | tablet · oral | MYLAN | Prescription | 3 May 2013 |
| CANDESARTAN CILEXETIL | 4MG; 8MG; 16MG; 32MG | tablet · oral | MACLEODS PHARMS | Prescription | 5 Dec 2016 |
| CANDESARTAN CILEXETIL | 32MG | tablet · oral | ALEMBIC | Prescription | 20 Jun 2017 |
| CANDESARTAN CILEXETIL | 4MG; 8MG; 16MG; 32MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 23 Aug 2017 |
| CANDESARTAN CILEXETIL | 4MG; 8MG; 16MG | tablet · oral | ALEMBIC | Prescription | 4 Dec 2018 |
| CANDESARTAN CILEXETIL | 8MG; 16MG; 32MG | tablet · oral | PRINSTON INC | Prescription | 21 Aug 2023 |
| CANDESARTAN CILEXETIL | 4MG; 8MG; 16MG; 32MG | tablet · oral | APOTEX | Discontinued | 10 Jan 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-CANDESARTAN TABLETS | 02500795 | 8 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CANDESARTAN TABLETS | 02500809 | 16 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CANDESARTAN TABLETS | 02500817 | 32 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-CANDESARTAN TABLETS | 02541289 | 4 MG | TABLET · ORAL | APOTEX INC |
| APO-CANDESARTAN TABLETS | 02541297 | 8 MG | TABLET · ORAL | APOTEX INC |
| APO-CANDESARTAN TABLETS | 02541300 | 16 MG | TABLET · ORAL | APOTEX INC |
| APO-CANDESARTAN TABLETS | 02541319 | 32 MG | TABLET · ORAL | APOTEX INC |
| ATACAND | 02239090 | 4 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| ATACAND | 02239091 | 8 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| ATACAND | 02239092 | 16 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| ATACAND | 02311658 | 32 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| AURO-CANDESARTAN | 02445786 | 4 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CANDESARTAN | 02445794 | 8 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CANDESARTAN | 02445808 | 16 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CANDESARTAN | 02445816 | 32 MG | TABLET · ORAL | AURO PHARMA INC |
| CANDESARTAN | 02377934 | 8 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CANDESARTAN | 02377942 | 16 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CANDESARTAN | 02388707 | 8 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CANDESARTAN | 02388715 | 16 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CANDESARTAN | 02422069 | 32 MG | TABLET · ORAL | PRO DOC LIMITEE |
| CANDESARTAN | 02528258 | 4 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CANDESARTAN | 02528266 | 32 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| JAMP-CANDESARTAN | 02386518 | 8 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CANDESARTAN | 02386526 | 16 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CANDESARTAN | 02386534 | 32 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
27 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ATACAND 16 MG TABLET | $7.85024 | per EA | 22 Jul 2026 |
| US NADAC | ATACAND 32 MG TABLET | $9.90376 | per EA | 23 Sep 2026 |
| US NADAC | CANDESARTAN CILEXETIL 16 MG TB | $0.47843 | per EA | 23 Sep 2026 |
| US NADAC | CANDESARTAN CILEXETIL 32 MG TB | $0.51886 | per EA | 23 Sep 2026 |
| US NADAC | CANDESARTAN CILEXETIL 4 MG TAB | $0.56857 | per EA | 23 Sep 2026 |
| US NADAC | CANDESARTAN CILEXETIL 8 MG TAB | $0.5364 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Candesartan 16mg tablets | £1.32 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Candesartan 2mg tablets | £0.86 | 7 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Candesartan 32mg tablets | £1.66 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Candesartan 4mg tablets | £0.91 | 7 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Candesartan 8mg tablets | £1.24 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 20 Aug 2020 ATACAND HCT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions - US FDA 24 Jun 2020 ATACAND — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Drug Interactions; Use in Specific Populations
Combinations containing Candesartan
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.